key take appreciate I'll you with today. my Thank Starting Slide on joining call like open from I'd the away XX, Good afternoon, We Haywood. our you you, messages the remarks everyone. call. to
securing positives Bavarian on million on clear discussed several the Travel We completing successfully business secured credit initiatives ACAMXXXX its government by quarter. amendment the a to sale order critical maturity the extends U.S. for were and that facility closing followed we in an $XXX our last our through call, to XXXX. the May of from our to there Nordic First, Health
continued our Canada. sales as saw adjusted And our over-the-counter provide also U.S. in strength of of launch Nasal as We by well prior we interest favorable we delivered in trends which guidance NARCAN accelerating strong the revenue, as for and EBITDA. prepare Spray, product. exceeded the near-term public tailwind momentum driven These market a in strong
our CDMO growth both is to Second, decision implications. and deemphasize near-term in immediate
growth change is the driver impairment our quarter. in While the committed customers, second in existing principal asset expectations we are reported charge CDMO to the the serving behind
we reducing operational contributor Additionally, Bayview $XXX which footprint the a we of announced of over facility, the major savings today. annualized million are to our is significantly earlier
and Third, XXXX clear while approval this U.S. we for long-term countermeasures for our stage continued franchises. remain medical of in on by with for prospects business, dialogue lowered CYFENDUS our the procurement we confident is have U.S. in The sets positive recent the government, product. expectations based and the anthrax for a smallpox revenue government the
expected funding for and we reduced, XXXX procurement as the levels will of XXXX. in available anticipate procurement transition, as to this is soon be increased Given be
U.S. of piece procurement In addition, that while we the next remains government's into a strategy, preparedness TEMBEXA smallpox TEMBEXA understand periods. is being of core the future deferred
cost return announcement to Finally, accelerate further streamline our profitability. reflects structure our and decisive action to this morning's
respond public across maintaining for also vaccine, mentioned And Rockville In while to are sites volumes response the our manufacturing I procurement changes reducing we related in the of we addition in to U.S. preparedness our to to at government's government the Camden administrative general against evolving just support Bayview, the threats. functions. changes are health and reducing of needs infrastructure and critical smallpox operations in our
savings some the let's million numbers. turn in beginning While there With year, we to be will XXXX. this anticipate realized savings that, over of $XXX
As with highlights in Canada. $XXX retail public the prior revenues over market sales primarily total of net quarter and due U.S. the increased market EBITDA indicated million, NARCAN XX, adjusted measures million profitability ACAMXXXX sales by loss key And prior increase $XX and and year, in interest year, and $XX the the XX, million. of an from our expected, XX as adjusted second on versus the include Slides driven timing higher of to
the Diving CYFENDUS include Anthrax million items sales the increased lower sales in year Strategic of NARCAN by demonstrating quarterly of and BioThrax National U.S. offset $XXX than market demand deliveries continuing the of government's higher durability to than interest of into channel and strength deeper prior the to U.S. of and growing million revenues, MCM product Stockpile, Anthrasil. the of this $XX by prior Canada. the from driven due public timing the consistent sales important year,
for during offset outstanding exercise contractual And higher government RSDL delivery procure the sales due primarily a by million well by year U.S. to site of BAT Smallpox year the option $XX million customer CDMO combined of at a resolution the revenues obligation. partially MCM sales. $XXX lower $XX as CDMO full sales to product million and Other of of as higher sales prior prior of the ACAMXXXX. service customer's $XXX as quarter higher Canton the to the million, the work and the lease were due than with level
higher than million prior prior Cost due quarter CHIKV due to initiatives. of activities. and higher Turning CDMO NARCAN. product of partially of product Cost year higher than prior primarily and by costs production CDMO the the expenses. due $XXX to site, due reduced sales sales the $XX of of the in at million across offset to lower network, Camden the lower fees expense our transformation million a period; the primarily largely ACAMXXXX spend prior services the of supporting higher to to in of year R&D higher the SG&A reflecting investments prior quality the contributor than $XX $XX improvement year primarily additional than to was year significant professional program, divestiture of million which operating year,
in million CDMO quarter, incurred Finally, to the our at in fixed noncash of related $XXX sites charge a assets Maryland. we impairment
prior ACAMXXXX move more performance $XXX With the from million, reflecting the higher the adjusted revenues and the sales year, over during of were increase quarter. and year XX% volume prior an review gross impact that, an In segment Slide and the and by margin or product driven NARCAN $XXX favorable was let's a segment, million to mix. XX increase Products
an the in prior year, at by enhancement were primarily Services increase quality was negative adjusted period additional year versus Canton prior As recur, that the by from offset facility. not driven the $XX segment, gross $XX investments the initiatives the onetime and costs revenues improvement year, did an in partially million, million, margin for prior
as the net of touch select the our second down And cash was quarter, million. repayments amendment flow Operating to in in quarter We to cash existing debt million $XXX cash and were senior in maturity XX. connection $XX with Slide on was I'll facility. highlights. primarily Moving from of XXXX, credit and sheet due and on secured in debt negative March June sequentially extension balance our ended $XX capital with XX, position XX, million. expenditures flow the period the made
quarter, the offering initiated equity at-the-market or During we ATM our program.
gross For average per the stock share. $X.XX price of for million, proceeds of million X.X sold $X.X common shares of quarter, our representing we an
XX. see Turning Slides guidance. Please XX and to
million $XXX guidance in billion from our the million million, of are million follows: to other full press year forecasting decrease at offset strength by of in As billion, prior midpoint of revenues updating for being XXXX the $X NARCAN announced ongoing across to our guidance reduced evening, as a release as Anthrax a at $X.X services. we of this MCM Total $XXX $XX expectations We're is and $XXX our midpoint. decrease the products sales
of procurement for we secured, With anticipate approval product. the CYFENDUS recent continued U.S. this the government FDA by
expect of $XX million the of cadence million government smallpox latest we now MCM midpoint. at and the determines U.S. million, discussions the of sales $XXX U.S. reduction for a will volume the going $XXX purchases of expect our appropriate We defer to additional forward. TEMBEXA with on government purchases HHS, as Based
over reflecting increase Nasal $XXX interest Canada. and primarily the midpoint million, We're demand to from million an at sales forecasting U.S. Spray of the guidance, prior of from $XXX the public channel robust $XX million NARCAN
account as NARCAN of taking well our As expectations launch the regarding into OTC.
site reflecting We revenue expectations of reduction Camden million, million reduction $XXX as for up expect $XXX remediation sales $XX product. to the a million We're lower of efforts quality reduction to of $XX CDMO other to the million $XX at services primarily million and the sales Trobigard, focus revenue of midpoint, continues operationally. of back auto-injector our on anticipated primarily midpoint, reflecting million, $XX scale product to a at the forecasting
guidance by of $XXX midpoint discussed adjusted the We earlier. of EBITDA forecasting impact anticipate $XX offset partially of million $XXX a lower million the cost revenues, to the facility million, million from reduction to and $XXX adjusted We're impact primarily prior of net total million the metrics. the other reflecting loss range, decrease million, the actions $XXX profitability midpoint. at of to a $XX of at Shifting
midpoint forecasting from we're of to basis guidance volume XX% And range, impact finally, of the points XXX XX%, a lower and of reduction prior revenue, gross mix. the reflecting at adjusted margin the primarily
in emphasizing year. in to quarter, the will further XXXX of anticipation our to and weighted to quarter, towards second revenues $XXX As the that revenues we're the of half million profits $XXX heavily guiding be the third million more
comments. please for To XX Slide summary to turn conclude,
Our and delivered milestones. of on results we quarter variety second in a were strong, important the
existing are our We adapting while to on products to our continuing focus customers. serve business
across continuing to position. our continue we to decisive will strengthen And better to with our We action taking costs quality needs while our are align the and solidify compliance our financial customer organization.
my prepared the and so question-and-answer completes now to That the turn can over operator start that we remarks, call I'll session. Operator? the
